Bridgewest Perth Pharma, an Australia-based global pharmaceutical supply and manufacturing company, announced on Tuesday that it has named Cyrus K. Mirsaidi as the new global CEO of the company, including its pharmaceutical supplier division LumaCina, and its Contract Development and Manufacturing Organisation (CDMO) division NovaCina.

Mirsaidi has served as CEO of BioDuro-Sundia and board advisor at BioDuro-Sundia, following his role as president and CEO. He has served as president and CEO at Molecular Response, chairman and managing partner at BioSelective Capital Investments, advisor to Advent International and board member at Sanguine Biosciences. His present appointments within the company include the Investment Committee at Bridgewest Ventures New Zealand and member of the board of directors at BioOra, LLC.

Dr Masood Tayebi, co-founder and chief executive officer of Bridgewest Group, said: "We are thrilled to have Cyrus stepping into this important role. Cyrus is an exceptional leader that has skilfully affected lasting positive momentum within the biotech sector. He grew our portfolio company BioDuro-Sundia into one of the world's top CRDMOs with major operations in the US and China, now employing more than 3,000 exceptional staff. This is the same kind of growth and exciting future we see for Bridgewest Perth Pharma; we could not be in better hands."